Protein X, recently renamed dihydrolipoamide dehydrogenase-binding protein (E 3 BP), is required for anchoring dihydrolipoamide dehydrogenase (E 3 ) to the dihydrolipoamide transacetylase (E 2 ) core of the pyruvate dehydrogenase complexes of eukaryotes. DNA and deduced protein sequences for E 3 BP of the human pyruvate dehydrogenase complex are reported here. With the exception of only a single lipoyl domain, the protein has a segmented multi-domain structure analogous to that of the E 2 component of the complex. The protein has 46% amino acid sequence identity in its amino-terminal region with the second lipoyl domain of E 2 , 38% identity in its central region with the putative peripheral subunit-binding domain of E 2 , and 50% identity in its carboxyl-terminal region with the catalytic inner core domain of E 2 . The similarity in the latter domain stands in contrast to E 3 BP of Saccharomyces cerevisiae, which is quite different from its homologous transacetylase in this region. The putative catalytic site histidine residue present in the inner core domains of all dihydrolipoamide acyltransferases is replaced by a serine residue in human E 3 BP; thus, catalysis of coenzyme A acetylation by this protein is unlikely. Coexpression of cDNAs for E 3 BP and E 2 resulted in the formation of an E 2 ⅐E 3 BP subcomplex that spontaneously reconstituted the pyruvate dehydrogenase complex in the presence of native E 3 and recombinant pyruvate decarboxylase (E 1 ).
Protein X, recently renamed dihydrolipoamide dehydrogenase-binding protein (E 3 BP), is required for anchoring dihydrolipoamide dehydrogenase (E 3 ) to the dihydrolipoamide transacetylase (E 2 ) core of the pyruvate dehydrogenase complexes of eukaryotes. DNA and deduced protein sequences for E 3 BP of the human pyruvate dehydrogenase complex are reported here. With the exception of only a single lipoyl domain, the protein has a segmented multi-domain structure analogous to that of the E 2 component of the complex. The protein has 46% amino acid sequence identity in its amino-terminal region with the second lipoyl domain of E 2 , 38% identity in its central region with the putative peripheral subunit-binding domain of E 2 , and 50% identity in its carboxyl-terminal region with the catalytic inner core domain of E 2 . The similarity in the latter domain stands in contrast to E 3 BP of Saccharomyces cerevisiae, which is quite different from its homologous transacetylase in this region. The putative catalytic site histidine residue present in the inner core domains of all dihydrolipoamide acyltransferases is replaced by a serine residue in human E 3 BP; thus, catalysis of coenzyme A acetylation by this protein is unlikely. Coexpression of cDNAs for E 3 BP and E 2 resulted in the formation of an E 2 ⅐E 3 BP subcomplex that spontaneously reconstituted the pyruvate dehydrogenase complex in the presence of native E 3 and recombinant pyruvate decarboxylase (E 1 ).
The pyruvate dehydrogenase complex (PDC) 1 catalyzes the oxidative decarboxylation of pyruvate with the formation of CO 2 , acetyl-CoA, and NADH. The eukaryotic complex has 30 copies of a tetrameric (␣ 2 ␤ 2 ) pyruvate decarboxylase (E 1 ) component noncovalently bound along the edges of an icosahedral 60 meric dihydrolipoamide acetyltransferase (E 2 ) core (1) . Twelve copies of a homodimeric dihydrolipoamide dehydrogenase (E 3 ) component are believed held on the faces of the E 2 core by a corresponding number of monomeric E 3 -binding proteins (protein X, E 3 BP) (2, 3) . With the exception of E 3 BP, the role of each enzymatic component in the overall reaction catalyzed by the complex is basically understood. E 1 catalyzes a thiamine diphosphate-dependent oxidative decarboxylation of pyruvate and the reductive acetylation of a lipoyl residue covalently attached to the lipoyl domain of E 2 . E 2 then catalyzes transfer of the acetyl group to coenzyme A, leaving a reduced E 2 lipoyl group that the E 3 component uses as an electron source for FAD-dependent reduction of NAD ϩ to NADH. Called protein X because its function was not apparent at the time it was originally discovered to be a component of eukaryotic PDCs (4 -6), E 3 BP has generated considerable interest because of sequence similarity with E 2 (7-10) and evidence that it has a covalently bound lipoyl moiety (4, 6, 8, 11) . Its function was difficult to establish in early studies because of a very tight association with the E 2 core of the complex. Very elegant limited proteolysis and immunological studies (12, 13) provided the first evidence that protein X contributes to the binding and function of E 3 . Cloning of the E 3 BP gene of Saccharomyces cerevisiae (14) revealed a protein structure that resembles the E 2 component of yeast in its amino terminus but not the remainder of the molecule. Subsequent gene disruption studies provided definitive proof that protein X should be considered an E 3 -binding protein (15) . Questions left unsettled included whether mammalian E 3 BP is completely analogous to yeast E 3 BP, whether the lipoyl moiety of mammalian E 3 BP is functionally important for catalytic activity of the complex, and whether the inner core of the mammalian E 3 BP has transacetylase activity.
The deduced amino acid sequence for the first mammalian (human) E 3 BP is presented here. Although similar in their amino-terminal, lipoyl-bearing domains, the mammalian E 3 BP and the yeast E 3 BP are markedly different in their carboxylterminal regions. Indeed, the human E 3 BP is more homologous to mammalian E 2 throughout its primary sequence than it is to yeast E 3 BP. Previous evidence that the mammalian E 3 BP contains only a single lipoyl domain in its amino terminus (8) , rather than the two tandemly arranged lipoyl domains characteristic of mammalian E 2 , is confirmed. The active site histidine residue characteristic of transacetylases of all ␣-ketoacid dehydrogenase complexes is not conserved in the mammalian E 3 BP. cDNA (CAT ATG AGT CTT CCC CCG CAT CAG AAG GTT CC(A/C)TC GAG AGT TAC AAC AAC ATA GTG ATA GGT). The sequence coding for NdeI restriction site was added to sense primer, whereas the sequence coding for XhoI site was added to antisense primer (underlined). The respective NdeI/XhoI fragment was subcloned between NdeI and XhoI sites of pET-23a expression vector (Novagen) (plasmid PDHE223a). The fidelity of constructs was established by nucleotide sequencing.
The expression cassette for human E 2 (carrying T7 promoter, ribosome-binding site, cDNA for E 2 component, and T7 terminator) was cut from pPDHE223a with BglII and NaeI. Resulting DNA was purified, blunt-ended with T4 DNA polymerase, and ligated into the pACYC vector (New England Biolabs) cut with HindIII and blunt-ended with T4 DNA polymerase (plasmid PDHE2). Plasmids were transformed into competent TG-1 cells. Transformants were selected on YT agar plates containing 35 g/ml of chloramphenicol. Colonies that expressed chloramphenicol resistance were screened for the presence of inserts by PCR with the above primers.
Construction of a Bacterial Expression Vector for Human E 2 ⅐E 3 BP Subcomplex of the Pyruvate Dehydrogenase Complex-NcoI and EcoRI restriction sites flanking the coding region of E 3 BP cDNA were constructed by PCR with Pfu DNA polymerase. The sense, NcoI containing, primer (TGG CCC ATG GGT GAT CCC ATT AAG ATA CTA ATG) corresponds to bases 168 -191 of the E 3 BP cDNA. Antisense primer (CTT GAA TTC CTA GGC AAG TCG GAT AGG ATT CT) corresponds to bases 1492-1514 of the E 3 BP cDNA and contains an EcoRI restriction site. Resulting cDNA of approximately 1.3 kilobases was digested with NcoI/EcoRI and ligated between NcoI/EcoRI site of bacterial expression vector pET-28a (Novagen) (plasmid PDHE3BP28a). pPDHE3BP28a was digested with DraIII/SphI to obtain an E 3 BP expression cassette. This DNA was blunt-ended with T4 DNA polymerase and ligated into pPDHE2 plasmid cut with BamHI and blunt-ended with T4 DNA polymerase (plasmid PDHE2/E3BP). Resulting plasmids were transformed into competent TG-1 cells. Transformants were selected on TY agar containing chloramphenicol. Plasmids carrying both cDNAs were identified by PCR. Construction of the bacterial expression vector for E 1 component of PDC (plasmid PDHE1) has been described elsewhere (16) .
Expression of Recombinant Polypeptides in Escherichia coli-Competent BL21(DE2) cells obtained from Novagen were transformed with pPDHE2 or pPDHE2/E3BP plasmids. Transformants were selected on TY agar plates containing 35 g/ml chloramphenicol. Several colonies displaying antibiotic resistance were tested for their ability to express recombinant polypeptides and were used to prepare glycerol stocks. For expression experiments, 10 l of glycerol stock (pPDHE1 was transformed in BL21(DE3)pLys cells) was inoculated into 1 liter of M9ZB medium supplemented with 35 g/ml chloramphenicol or 100 g/ml ampicillin for pPDHE2/E3BP and pPDHE1 plasmids, respectively. The cells were allowed to grow at 37°C until the A 600 reached 0.6 -0.7. At this point, the cultures were shifted to room temperature. After temperature equilibration, cultures were supplemented with 50 g/ml thiamin for pPDHE1 or 0.2 mM lipoic acid for pPDHE2/E3BP and induced with 0.4 mM isopropyl-␤-D-thiogalacto-pyranoside. Cells were cultured for another 20 -24 h at room temperature and then harvested.
Partial Purification of the Recombinant Proteins-Harvested cells were resuspended in 75 ml of buffer A (50 mM potassium phosphate, pH 7.4, 0.5 mM EDTA, 20 mM ␤-mercaptoethanol, 100 mM KCl) supplemented with 0.5% Triton X-100 plus a mixture of protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, 10 g/ml pepstatin A, 20 g/ml leupeptin, 0.2 mM benzamidine, 1% aprotinin). Cells were sonicated five times for 15 s on ice with 1-min intervals. Extracts were clarified by centrifugation at 40,000 ϫ g for 20 min. Clear extracts containing E 1 and either E 2 or E 2 ⅐E 3 BP subcomplexes were combined and recombinant proteins were precipitated with 12% (w/v) polyethylene glycol (PEG, Sigma)-8000 at 4°C for 20 min. This 12% PEG pellet was resuspended in 30 ml of buffer A containing 0.1% Triton X-100 and applied on a Sepharose 4B column (bed volume, 500 ml) equilibrated with the same buffer. Column fractions (5 ml) were assayed by PDC activity and Western blot analysis. Pooled fractions containing human PDC components were centrifuged at 150,000 ϫ g for 10 -12 h. Precipitated PDC was resuspended in a small volume of buffer A containing 0.5% Triton X-100 and protease inhibitors and stored at Ϫ70°C.
Other Procedures-Activity of PDC was assayed by the reduction of NAD ϩ to NADH as described previously (17) . Five units of porcine dihydrolipoamide dehydrogenase (Sigma) and 0.5 mM pyruvate were used in the assay. SDS-PAGE analysis was performed according to Laemmli (18) . Procedure for Northern analysis was as described elsewhere (19) . Human heart poly(A) ϩ RNA was obtained from CLON-TECH. Protein was determined according to Lowry et al. (20) with bovine serum albumin as a standard.
RESULTS AND DISCUSSION
Primary Structure of Human E 3 BP-A search of the expressed sequence tag data base of the National Center for Biotechnology Information revealed four clones that encoded protein sequences similar to those reported previously (7, 8, 10) for the amino terminus and an internal region of bovine E 3 BP. Two of these clones (H58032 and T77385) were sequenced and found identical to one another except that T77385 is 370 base pairs shorter at its 5Ј end. Clone H58032 has an open reading frame of 1503 base pairs that encodes a protein of 501 amino acid residues with a calculated molecular weight of 54,085 (Fig.  1) . Evidence that this cDNA encodes E 3 BP is provided by a comparison of the deduced protein sequence with the previously published (7, 8, 10) amino-terminal sequences of bovine heart and kidney E 3 BP as well as internal sequences obtained with Arg C proteolytic fragments of these proteins (Table I) . Although no previous data for the human protein are available in the literature, the almost perfect match (45 of 50 residues) with the bovine protein indicates that the cDNA obtained in this study encodes human E 3 BP. Based on the amino-terminal sequence of 22 amino acids published previously for bovine heart E 3 BP (Table I) , the mature form of E 3 BP is assumed to start after a 53-amino acid presequence that has numerous Arg, Ser, and Leu residues arranged in an order consistent with other mitochondrial targeting sequences (21) . The assignment of where the mature protein begins is provisional, however, because the mature native human protein has not been subjected to direct amino acid sequencing and there is disagreement in the literature as to whether the amino terminus of the bovine protein is free or blocked (7, 8) . If it is assumed that mature E 3 BP of human starts at the same residue found for the bovine heart protein, the human mature protein has 448 amino acids with a calculated molecular weight of 48,040, in reasonably good agreement with the molecular weight of 50,000 estimated by SDS-PAGE (4 -6). The sequence that corresponds to the previously determined sequences of the protease Arg C-derived fragments of bovine heart and kidney E 3 BP follows an Arg-130 in the human protein. Cleavage of the human protein at this residue would generate polypeptides with calculated molecular weights of 14,033 and 34,025, in good agreement with the estimated molecular weights (15,000 and 35,000) by SDS-PAGE of the polypeptides produced by protease Arg C cleavage of the bovine proteins (10, 22) .
Size of the Message Encoding E 3 BP and Chromosomal Loca-tion of the E 3 BP Gene-Northern blot analysis of human heart poly(A) ϩ RNA (CLONTECH) using 32 P-labeled cDNA for E 3 BP as a probe revealed a single hybridizing message of approximately 2.7 kilobases (data not shown), indicating cDNA of clone H58032 is almost complete. The DNA sequence encoding this message is located on chromosome 11 in the region p12-13 (National Center for Biotechnology Information Human Gene Map). It is interesting that the human E 2 gene has also been mapped to chromosome 11 but in a region (q21-23) far removed from that of the E 3 BP gene. Lack of any long stretches of identical nucleotide (not shown) and amino acid sequences (presented and discussed below) in E 2 and E 3 BP also indicates that different genes encode these proteins.
Expression, Reconstitution, and Partial Purification of the Human Pyruvate Dehydrogenase Complex-E 3 BP is an essential component of PDC because it positions E 3 to accept electrons from the reduced lipoyl group of the E 2 component (12, 13, 15) . Since the only function of E 3 BP may be to anchor E 3 to the complex and E 3 BP may not have an intrinsic catalytic activity of its own, proof that the cDNA characterized in this study encodes E 3 BP would best be provided by reconstitution of the overall reaction catalyzed by PDC. Without the presence of E 3 BP as an integral component of the complex, the enzymatic activity of the complex for its complete reaction (pyruvate ϩ NAD ϩ ϩ CoA 3 acetyl-CoA ϩ NADH ϩ CO 2 ) would be expected to be very low for want of high affinity binding of E 3 to the complex. With E 3 BP present in the complex, E 3 should bind and reconstitute PDC with a high specific activity.
The mammalian PDC consists of three single enzyme subcomplexes capable of self-assembly: 1) E 1 subcomplex (tetramer of two E 1 ␣ and two E 1 ␤ subunits); 2) E 2 ⅐E 3 BP subcomplex (consists of 60 copies of E 2 and 12 copies of E 3 BP); and 3) E 3 subcomplex (dimer of two identical subunits). This modular organization allows for independent expression of the different single enzyme subcomplexes, which can then be mixed for reconstitution of the multienzyme complex. We took advantage of this fact, generating the catalytically active E 1 subcomplex by co-expression of cDNAs for E 1 ␣ and E 1 ␤ subunits and independently generating the catalytically active dihydrolipoamide acyltransferase or E 2 ⅐E 3 BP subcomplex by co-expression of cDNAs for E 2 and E 3 BP. For comparison purposes, the dihydrolipoamide acyltransferase component lacking E 3 BP was obtained by expression of the cDNA for E 2 alone. The dihydrolipoamide dehydrogenase subcomplex from porcine heart is commercially available in excellent purity, making its expression for the reconstitution studies unnecessary.
Reconstitution of the PDC was achieved by mixing extracts of E. coli in which the E 1 subcomplex had been expressed with extracts of E. coli in which either the E 2 ⅐E 3 BP complex or E 2 alone subcomplex had been expressed. Reaction mixtures containing expressed E 1 alone plus porcine E 3 , expressed E 2 ⅐E 3 BP alone plus porcine E 3 , or expressed E 2 alone plus porcine E 3 did not show PDC activity above that due to the native bacterial enzyme activity present in these extracts (Fig. 2) . However, combining extracts containing E 1 and E 2 ⅐E 3 BP in a reaction cocktail containing porcine E 3 reconstituted the mammalian PDC as evidenced by a more than 3-fold increase in activity above that of the native bacterial enzyme activity (Fig. 2) . Combining extracts containing E 1 with extracts containing E 2 but lacking E 3 BP in a reaction mixture containing the same amount of porcine E 3 resulted in no increase in PDC activity, showing that the cDNA encodes for E 3 BP and confirming its requirement for the reaction catalyzed by the complex.
To establish whether E 3 BP physically associates with other FIG. 1. Nucleotide and deduced amino acid sequence of human E 3 BP. Numbering begins at the 5Ј end for the nucleotide sequence and at position Ϫ53 for the deduced amino acid sequence. The mitochondrial targeting sequence is proposed to correspond to amino acid residues Ϫ53 to Ϫ1. Amino acid sequences with homology to previously reported amino-terminal and internal amino acid sequences of bovine heart and kidney E 3 BP are underlined. components of the PDC, extracts of E. coli containing the different recombinant proteins were combined to reconstitute subcomplexes with and without E 3 BP. The E 1 ⅐E 2 ⅐E 3 BP subcomplex, produced by combining extracts containing E 1 and E 2 ⅐E 3 BP, and the E 1 ⅐E 2 subcomplex, produced by combining extracts containing E 1 and E 2 , were then partially purified by PEG precipitation and gel filtration on Sepharose 4B. Both subcomplexes eluted from the gel filtration column as large aggregates right after the void volume, indicative of assembly of macromolecular complexes from the components (data not shown). The isolated E 1 ⅐E 2 ⅐E 3 BP subcomplex added to a reaction mixture containing porcine E 3 exhibited a specific enzyme activity of 12 units/mg of protein. This value is lower but still quite respectable relative to previously reported specific activities (18 -23 units/mg of protein) for native bovine enzymes (23) , particularly since the subcomplex was only partially purified. Incomplete lipoylation of the E2 component could also be a contributing factor. In contrast to the high activity of the E 1 ⅐E 2 ⅐E 3 BP subcomplex, the isolated E 1 ⅐E 2 subcomplex had a much lower specific activity (Ͻ0.8 units/mg of protein) when assayed under the same conditions. SDS-PAGE analysis of the respective preparations revealed that the catalytically active subcomplex contains predominant protein bands corresponding to the molecular weights of E 1 ␣, E 1 ␤, E 2 , and E 3 BP (Fig. 3) . In contrast, the much less active subcomplex obtained by expression of the E 2 cDNA without E 3 BP cDNA lacks the protein corresponding to E 3 BP. These findings provide evidence that the E 3 BP is physically associated with E 2 and confirm that it is required for PDC activity.
Comparison of the Amino Acid Sequences of Human E 3 BP and Human E 2 -Analysis of the human E 3 BP amino acid sequence indicates a structure quite similar to human E 2 , i.e. a segmented domain structure joined by linker regions rich in alanine and proline residues (Fig. 4A) . Overall sequence identity is 43% for the two proteins. One difference is that E 3 BP has one putative lipoyl-bearing domain in its amino-terminal region rather than the two tandemly repeated lipoyl-bearing domains present in E 2 . Residues 4 -83 of E 3 BP exhibit 44% sequence identity with the first lipoyl-bearing domain and 46% identity with the second lipoyl-bearing domain of E 2 (Fig. 4B) . Thus, the alignment can be made with either lipoyl-bearing domain, but because of the slightly greater degree of homology, the E 3 BP sequence has been aligned in Fig. 4 with the second lipoyl-bearing domain of E 2 . That E 3 BP should have a lipoyllysine residue in its amino-terminal region is expected from several previous studies demonstrating acetylation of this protein upon incubation of PDC with either radioactive pyruvate or acetyl-CoA (4, 6, 8, 11) . Lipoyllysine residues are typically found to occur 43-44 residues from the amino terminus of mammalian E 2 proteins (26) . A lysine residue is located at assigned position 44 in the deduced sequence of mature E 3 BP, and this lysine occurs in a typical consensus sequence for a lipoyl-attachment site (branched chain residue-Glu-Ser/ThrAsp-Lys-Ala-Xaa-branched chain residue) (26) and is, therefore, highly likely to be the site of lipoylation. The existence of a glycine at position 55 is of significance because of recent evidence that a glycine residue situated 11 residues to the carboxyl-terminal side of a lipoylation site is required for lipoylation of E 2 by lipoyltransferases (27) .
Human E 3 BP also has an internal region that exhibits considerable sequence identity with the putative E 1 /E 3 -binding domain (28) of human E 2 (Fig. 4B) , a relationship pointed out previously by Sanderson et al. (10) in their analysis of the first 23 amino-terminal residues of an Arg C proteolytic fragment of bovine E 3 BP. Thirty-eight percent sequence identity occurs in this domain (E2 residues 271 to 303 versus E 3 BP residues 131 FIG. 2. Reconstitution of pyruvate dehydrogenase activity from subcomplexes formed from recombinant proteins expressed in E. coli. E. coli extracts were combined in 1 ml of PDC assay mixture (see "Experimental Procedures") containing 5 units/ml of the porcine E 3 component as follows. Panel A, 5 l of extract containing recombinant E 1 , 5 l of mixture of extracts containing recombinant E 1 and recombinant E 2 ⅐E 3 BP, and 5 l of extract containing recombinant E 2 ⅐E 3 BP; panel B, 5 l of extract containing recombinant E 1 , 5 l of mixture of extracts containing recombinant E 1 and recombinant E 2 , and 5 l of extract containing recombinant E 2 . After 2 min of preincubation at 30°C, reaction was initiated with pyruvate (0.5 mM) and followed by production of NADH. were combined with extracts containing either recombinant E 2 ⅐E 3 BP or recombinant E 2 alone. The subcomplexes were then partially purified by PEG precipitation, Sepharose 4B chromatography, and sedimentation by centrifugation (see "Experimental Procedures"). Protein bands corresponding to the recombinant subunits of the subcomplexes are identified on the gels. The minor protein bands correspond to subunits of the E. coli pyruvate dehydrogenase and ␣-ketoglutarate dehdydrogenase complexes that are present as contaminants in these partially purified preparations of recombinant human PDCs.
to 163) where E 1 is believed to bind to E 2 and where E 3 most likely binds to E 3 BP. Further support that E 3 binds in this region to E 3 BP is provided by considerable sequence identity with E 3 -binding domains of the E 2 components of human branched chain ␣-ketoacid dehydrogenase complex (30%) (26, 29) and E. coli ␣-ketoglutarate dehydrogenase complex (50%) (30) . It is noteworthy that the protease Arg C cleavage site of E 3 BP (7, 10) is located adjacent to the amino-terminal side of the E 1 /E 3 binding-domain (Fig. 4B) . This is consistent with the previous suggestion of Sanderson et al. (10) that exposure of this domain with disruption of its structure most likely accounts for loss of E 3 binding upon cleavage of E 3 BP at the Arg C proteolytic site (7) .
The carboxyl-terminal regions of E 3 BP and E 2 are remarkably similar (Fig. 4B) . This is the inner core domain of E 2 where acetyl transferase activity as well as the self-assembly sequences are located. These proteins share 50% sequence identity in this region, beginning with residues 221 and 334 of E 3 BP and E 2 , respectively, and extending to their carboxyl termini. The carboxyl-terminal region of human E 3 BP lacks the highly conserved histidine residue found in the active site motif of all dihydrolipoamide acyltransferases. This histidine residue is invariably present in the highly conserved sequence of DHRXXDG in proteins with acyltransferase activity (31) (32) (33) (34) . The corresponding sequence in human E 3 BP is DSRXXDD (residues 221 to 226; Fig. 4B) . Thus, the active site histidine is replaced by a serine residue, and the carboxyl-terminal aspartate of the motif is replaced by a glycine residue, making it unlikely that this protein possesses acetyltransferase activity.
Based on a comparison of the primary sequences E2 of different species, two domains (residues 428 to 440 and 462 to 483) within the carboxyl-terminal region of E2 have been proposed involved in homo-and hetero-subunit interactions (28) . Although not established that these domains are interaction sites between E2 subunits, it is interesting to note that 9 of 13 residues in the first domain and 17 of 22 residues in the second are identical in E 3 BP and E 2 .The hinge regions separating the three major segments of E 3 BP and E 2 show the least sequence identity (15%) of any region of these proteins (Fig. 4B) . The hinge of E 2 that connects lipoyl-bearing domain 2 with the peripheral subunit binding domain is rich in both proline and alanine residues. The corresponding region of E 3 BP is rich in proline but contains no alanine residues. Collagenase specifically cleaves within this hinge of E 2 because it contains an amino acid sequence (PAGP) recognized by this protease. Absence of this sequence from the hinge of E 3 BP prevents cleavage by collagenase, accounting for the specific removal of lipoylbearing domains from E 2 by collagenase digestion of the PDC (35) . The hinge separating the E 1 /E 3 -binding domain from the inner core is rich in proline and alanine residues in both proteins, but this domain is 28 residues longer in E 3 BP and consequently has many more proline and alanine residues in this region than E 2 .
Lipoyl-bearing proteins have invariably been found to migrate on SDS-PAGE gels with aberrantly high molecular weights (29, 36) , a feature attributed to an extended region of helical structure due to domains rich in alanine and proline residues (37). It is not apparent why this disparity between SDS-PAGE-estimated molecular weight (50,000) and amino acid content-calculated molecular weight (48,040) is not observed for E 3 BP.
Comparison of the Amino Acid Sequences of Human E 3 BP and Yeast E 3 BP-The human E 3 BP shows significant sequence similarity to the yeast E 3 BP only in amino-terminal, lipoylbearing domains of these proteins (49% identity between residues 4 -83) (Fig. 4B) . In this region, both proteins have the signature motif of a lipoyl-bearing domain as discussed above in the sequence comparison with E 2 . Beyond residue 83, however, very little sequence similarity is found for these proteins that have been assigned a similar function in their respective complexes. The yeast protein lacks a well defined proline-alanine-rich domain that would readily identify a hinge region. On the other hand, a short sequence exists between residues 166 and 175 that has significant homology to sequences within the E 1 /E 3 -binding domains of human E 2 and E 3 BP. Conservation of this sequence in both the human and the yeast forms of E 3 BP (24); HE 3 BP, human E 3 BP amino acid sequence deduced from DNA in this study; and YE 3 BP, S. cerevisiae E 3 BP amino acid sequence (15) . Multiple sequence alignment was made according to the MACAW program (25) . Conserved amino acids of all three proteins are shown by the black shading and white type. Conserved amino acids of human E 2 and human E 3 BP are shown by dark gray shading and black type. Sites for protease Arg C cleavage of E 3 BP and collagenase cleavage of E 2 are indicated by arrows. Amino acids defining lipoyl-bearing domains, hinges, E 1 /E 3 binding domains, and inner core regions are indicated by double-headed arrows. Lipoylation site lysine residues are indicated by asterisks. Catalytic site histidine residue of human E 2 is identified by a # sign.
suggests this motif may be particularly important for E 3 binding. However, it is known that E 3 -deficient PDC from beef heart cannot be reconstituted with yeast E 3 (10) , a finding that presumably reflects poor binding of yeast E 3 to the mammalian E 3 BP as a consequence of marked differences in sequence and therefore structure of the E 3 -binding domains of yeast and mammalian E 3 -binding proteins.
The carboxyl-terminal region of yeast E 3 BP shows no sequence similarity with either human E 2 or E 3 BP (Fig. 4B) . The active site motif DHRXXDG characteristic of dihydrolipoamide acyltransferases is not present in yeast E 3 BP, and no evidence has been presented for acyltransferase activity with either the native or recombinant proteins (38, 39) .
The remarkable differences between yeast E 3 BP and mammalian E 3 BP coupled with the remarkable similarity between mammalian E 2 and mammalian E 3 BP raise interesting questions, not the least of which is whether anchoring E 3 to E 2 is the only function of mammalian E 3 BP. We are particularly interested in a possible role for this protein in mediating regulation of the activity of the various isoenzymes of pyruvate dehydrogenase kinase that have been discovered recently (19, 40) . The availability of the recombinant E 3 BP and the capability for reconstitution of PDC completely from recombinant proteins should facilitate future studies of the function of protein X.
